Wells Fargo raised the firm’s price target on Corteva (CTVA) to $85 from $77 and keeps an Overweight rating on the shares. The firm is encouraged by the resolution to its litigation with Bayer, and another year of positive strong EBITDA growth. In addition, the spin appears to remain on schedule, Wells adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTVA:
- Corteva price target raised to $80 from $74 at Citi
- Corteva: Fairly Valued Ahead of 2026 Separation, Supporting a Neutral (Hold) Rating
- Corteva downgraded to Neutral from Overweight at JPMorgan
- Corteva Earnings Call Highlights Margin Gains and Upside
- Corteva reports Q4 adjusted EPS 22c, consensus 22c